Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nizar A Mullani

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Skinmed|March 24, 2005
DermLite II: an innovative portable instrument for dermoscopy without the need of immersion fluidsPeter Arrazola, Nizar A Mullani, William Abramovits
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2008
Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flowNizar A Mullani, Roy S Herbst, Roger G O'Neil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumorsDarren W Davis, Yu Shen, Nizar A Mullani, et al.
Journal of Computer Assisted Tomography|May 30, 2009
Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison studyChaan S Ng, Yoshihisa Kodama, Nizar A Mullani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Phase I study of recombinant human endostatin in patients with advanced solid tumorsRoy S Herbst, Kenneth R Hess, Hai T Tran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatinRoy S Herbst, Nizar A Mullani, Darren W Davis, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Skinmed|March 24, 2005
DermLite II: an innovative portable instrument for dermoscopy without the need of immersion fluidsPeter Arrazola, Nizar A Mullani, William Abramovits
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2008
Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flowNizar A Mullani, Roy S Herbst, Roger G O'Neil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumorsDarren W Davis, Yu Shen, Nizar A Mullani, et al.
Journal of Computer Assisted Tomography|May 30, 2009
Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison studyChaan S Ng, Yoshihisa Kodama, Nizar A Mullani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Phase I study of recombinant human endostatin in patients with advanced solid tumorsRoy S Herbst, Kenneth R Hess, Hai T Tran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatinRoy S Herbst, Nizar A Mullani, Darren W Davis, et al.
Pageof 1